170 related articles for article (PubMed ID: 16149716)
1. Evaluation of antibacterial in vitro activity of moxifloxacin and its effects on pulmonary clearance of Klebsiella pneumoniae in an animal experimental model.
Drago L; De Vecchi E; Nicola L; Gismondo MR
Arzneimittelforschung; 2005; 55(8):473-7. PubMed ID: 16149716
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
3. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
7. In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains.
Rodríguez-Cerrato V; García P; Del Prado G; García E; Gracia M; Huelves L; Ponte C; López R; Soriano F
J Antimicrob Chemother; 2007 Nov; 60(5):1159-62. PubMed ID: 17827138
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
Cafini F; Alou L; Sevillano D; Valero E; Prieto J;
Int J Antimicrob Agents; 2004 Oct; 24(4):334-8. PubMed ID: 15380257
[TBL] [Abstract][Full Text] [Related]
9. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
[TBL] [Abstract][Full Text] [Related]
10. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Alou L; Giménez MJ; Sevillano D; Aguilar L; Cafini F; Echeverría O; Pérez-Trallero E; Prieto J
J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
[TBL] [Abstract][Full Text] [Related]
11. High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy.
Murillo O; Pachón ME; Euba G; Verdaguer R; Tubau F; Cabellos C; Cabo J; Gudiol F; Ariza J
J Infect; 2009 Mar; 58(3):220-6. PubMed ID: 19217166
[TBL] [Abstract][Full Text] [Related]
12. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
[TBL] [Abstract][Full Text] [Related]
13. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003.
Johnson AP; Lamagni TL; Wale M; Cavendish S; Bishop L; Alhaddad N; Warner M; Livermore DM; Duckworth G; George RC
Int J Antimicrob Agents; 2005 Jun; 25(6):539-41. PubMed ID: 15890501
[TBL] [Abstract][Full Text] [Related]
15. Changes in serum sensitivity and hydrophobicity in a clinical isolate of Klebsiella pneumoniae treated with subinhibitory concentrations of aminoglycosides.
Hostacká A
Zentralbl Bakteriol; 1998 Dec; 288(4):519-26. PubMed ID: 9987190
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations.
Schubert S; Dalhoff A; Stass H; Ullmann U
Infection; 2005 Dec; 33 Suppl 2():15-21. PubMed ID: 16518707
[TBL] [Abstract][Full Text] [Related]
17. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Chemother; 2004 Feb; 16(1):30-7. PubMed ID: 15077996
[TBL] [Abstract][Full Text] [Related]
18. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae.
Poudyal A; Howden BP; Bell JM; Gao W; Owen RJ; Turnidge JD; Nation RL; Li J
J Antimicrob Chemother; 2008 Dec; 62(6):1311-8. PubMed ID: 18922815
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial polymers as therapeutics for treatment of multidrug-resistant Klebsiella pneumoniae lung infection.
Lou W; Venkataraman S; Zhong G; Ding B; Tan JPK; Xu L; Fan W; Yang YY
Acta Biomater; 2018 Sep; 78():78-88. PubMed ID: 30031912
[TBL] [Abstract][Full Text] [Related]
20. Impact of plasma protein binding on antimicrobial activity using time-killing curves.
Zeitlinger MA; Sauermann R; Traunmüller F; Georgopoulos A; Müller M; Joukhadar C
J Antimicrob Chemother; 2004 Nov; 54(5):876-80. PubMed ID: 15472003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
